NDAORALPOWDER
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
23
Mechanism of Action
unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.
Clinical Trials (5)
A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Started Dec 2023
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate
Started Nov 2016
18 enrolled
Healthy Subjects
Fosrenol Post-marketing Surveillance in Japan
Started Oct 2013
343 enrolled
HyperphosphatemiaKidney Disease
A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis
Started Feb 2013
63 enrolled
Chronic Kidney DiseaseHyperphosphatemia
Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
Started Dec 2010
35 enrolled
Chronic Kidney Disease
Loss of Exclusivity
LOE Date
Dec 1, 2030
57 months away
Patent Expiry
Dec 1, 2030